Diaverum
Diaverum is a global provider of renal care services and the largest independent provider in Europe with more than 400 clinics in Africa, Asia, Europe and Latin America.[1]
 | |
| Privately held | |
| Industry | Healthcare |
Key people | Dimitris Moulavasilis, President and CEO |
| Services | Renal care and dialysis |
Number of employees | 11,000 (2019) |
| Website | www.diaverum.com |
History
Diaverum was originally part of the Swedish company Gambro, founded in Lund, Sweden in 1964.[2] Gambro opened its first dialysis clinic in Lund in 1991. The clinic activities expanded under the name Gambro Healthcare and by 2005 the company managed 150 dialysis clinics worldwide. Gambro Healthcare was divested from Gambro in 2007 and taken over by Bridgepoint Capital, a major private healthcare investor in Europe, and the company management. The name Diaverum was adopted in 2008. Today, Diaverum is led by Dimitris Moulavasilis, President and CEO, and his executive team.[3]
Service offer
Diaverum provides life enhancing renal care to patients with chronic kidney disease, with the aim to enable patients to live a fulfilling life. Diaverum describes itself as renal care provider offering renal care from preventive and early stage to renal replacement therapies:
- In-clinic haemodialysis
- Peritoneal dialysis
- Preventive care
- Other medical services such as vascular access and transplantation
External links
- Strippoli, Giovanni FM; Palmer, Suetonia C; Ruospo, Marinella; Natale, Patrizia; Saglimbene, Valeria; Craig, Jonathan C; Pellegrini, Fabio; Petruzzi, Massimo; De Benedittis, Michele; Ford, Pauline; Johnson, David W; Celia, Eduardo; Gelfman, Ruben; Leal, Miguel R; Torok, Marietta; Stroumza, Paul; Bednarek-Skublewska, Anna; Dulawa, Jan; Frantzen, Luc; Ferrari, Juan Nin; Del Castillo, Domingo; Hegbrant, Jorgen; Wollheim, Charlotta; Gargano, Letitzia (2013). "Oral disease in adults treated with hemodialysis: Prevalence, predictors, and association with mortality and adverse cardiovascular events: The rationale and design of the ORAL Diseases in hemodialysis (ORAL-D) study, a prospective, multinational, longitudinal, observational, cohort study". BMC Nephrology. 14: 90. doi:10.1186/1471-2369-14-90. PMC 3685555. PMID 23597063.
- Maione, A; Nicolucci, A; Craig, J. C; Tognoni, G; Moschetta, A; Palasciano, G; Pugliese, G; Procaccini, D. A; Gesualdo, L; Pellegrini, F; Strippoli, G. F (2007). "Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial". Journal of Nephrology. 20 (6): 646–55. PMID 18046666.
- Strippoli, Giovanni FM (2010). "Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: The clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol". Trials. 11: 70. doi:10.1186/1745-6215-11-70. PMC 2903576. PMID 20534124.